A retrospective study of anlotinib in patients with persistent, recurrent or metastatic cervical and endometrial cancer

被引:0
作者
Xin, Lingli [1 ,2 ]
Ye, Mei [1 ]
Gao, Yuan [3 ]
Xiong, Qi [4 ]
Hou, Qingxiang [1 ]
机构
[1] Peoples Liberat Army PLA Rocket Force Characterist, Dept Obstet & Gynecol, Xinjiekou Outer St 16, Beijing 100088, Peoples R China
[2] Gen Hosp Chinese Peoples Liberat Army PLA, Dept Grad Adm, Beijing 100853, Peoples R China
[3] Gen Hosp Chinese Peoples Liberat Army PLA, Dept Obstet & Gynecol, Beijing, Peoples R China
[4] Gen Hosp Chinese Peoples Liberat Army PLA, Dept Oncol, Beijing, Peoples R China
关键词
Anlotinib; safety; immunotherapy; cervical cancer; endometrial cancer;
D O I
10.21037/tcr-24-272
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The prognosis of persistent, recurrent or metastatic cervical and endometrial cancer is poor. Anlotinib is a novel multitarget tyrosine kinase inhibitor (TKI). The efficacy and safety of anlotinib in patients with cervical and endometrial cancer need to be evaluated. Methods: We retrospectively analyzed the efficacy and safety of anlotinib in patients with persistent, recurrent or metastatic cervical and endometrial cancers between March 2020 and June 2023. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were analyzed. Results: The overall ORR and DCR were 24.14% and 55.17% respectively. The ORR and DCR in patients with cervical cancer were 25.00% and 56.25%; the ORR and DCR in patients with endometrial cancer were 23.08% and 53.85%. The patients received anlotinib plus immunotherapy had significantly higher rate of clinical benefit than those receiving anlotinnb alone (P=0.04). The DCR was significantly higher in patients receiving anlotinib combined with immunotherapy (DCR: 75.00% vs. 30.76%) than those without immunotherapy. The overall median PFS and OS were 12.2 months [95% confidence interval (CI): 6.6-17.8] and 22.3 months (95% CI: 20.9-23.7), respectively. The patients receiving anlotinib plus immunotherapy had significantly longer OS than those without immunotherapy [not reached vs. 12.5 months; hazard ratio (HR): 0.32 (95% CI: 0.1-0.99); P=0.04]. The most common AEs was fatigue (41.4%). Conclusions: Anlotinib might be a promising agent for persistent, recurrent or metastatic cervical and endometrial cancers with good tolerability. Moreover, anlotinib combined with immunotherapy showed synergistic antitumor effect.
引用
收藏
页码:3718 / 3728
页数:11
相关论文
共 41 条
[1]   Cancer and the Immune System: The History and Background of Immunotherapy [J].
Abbott, Maura ;
Ustoyev, Yelena .
SEMINARS IN ONCOLOGY NURSING, 2019, 35 (05)
[2]   Molecular landscape of recurrent cervical cancer [J].
Adiga, Divya ;
Eswaran, Sangavi ;
Pandey, Deeksha ;
Sharan, Krishna ;
Kabekkodu, Shama Prasada .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 157
[3]   Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer [J].
Bogani, G. ;
Monk, B. J. ;
Powell, M. A. ;
Westin, S. N. ;
Slomovitz, B. ;
Moore, K. N. ;
Eskander, R. N. ;
Raspagliesi, F. ;
Barretina-Ginesta, M. -P ;
Colombo, N. ;
Mirza, M. R. .
ANNALS OF ONCOLOGY, 2024, 35 (05) :414-428
[4]   Optimal Management for Stage IVB Endometrial Cancer: A Systematic Review [J].
Capozzi, Vito Andrea ;
Scarpelli, Elisa ;
De Finis, Alessandra ;
Rotondella, Isabella ;
Scebba, Davide ;
Gallinelli, Asya ;
Montrucchio, Carlotta ;
Martignon, Giulia ;
Leotta, Martina ;
Ghi, Tullio ;
Berretta, Roberto .
CANCERS, 2023, 15 (21)
[5]   Radiotherapy of cervical cancer [J].
Chargari, C. ;
Peignaux, K. ;
Escande, A. ;
Renard, S. ;
Lafond, C. ;
Petit, A. ;
Kee, D. Lam Cham ;
Durdux, C. ;
Haie-Meder, C. .
CANCER RADIOTHERAPIE, 2022, 26 (1-2) :298-308
[6]   Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma [J].
Chi, Yihebali ;
Fang, Zhiwei ;
Hong, Xiaonan ;
Yao, Yang ;
Sun, Ping ;
Wang, Guowen ;
Du, Feng ;
Sun, Yongkun ;
Wu, Qiong ;
Qu, Guofan ;
Wang, Shusen ;
Song, Jianmin ;
Yu, Jianchun ;
Lu, Yongkui ;
Zhu, Xia ;
Niu, Xiaohui ;
He, Zhiyong ;
Wang, Jinwan ;
Yu, Hao ;
Cai, Jianqiang .
CLINICAL CANCER RESEARCH, 2018, 24 (21) :5233-5238
[7]   Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs [J].
Choi, Ha Yeong ;
Chang, Ji-Eun .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (17)
[8]   Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy [J].
Choi, Yechan ;
Jung, Keehoon .
EXPERIMENTAL AND MOLECULAR MEDICINE, 2023, 55 (11) :2308-2319
[9]   Anlotinib in recurrent or metastatic endometrial cancer [J].
Cui, Qingli ;
Mao, Yuefeng ;
Hu, Yanhui ;
Ma, Dongyang ;
Liu, Huaimin .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 (09) :1147-1152
[10]   Management of Endometrial Cancer: Molecular Identikit and Tailored Therapeutic Approach [J].
D'Oria, Ottavia ;
Giannini, Andrea ;
Besharat, Aris Raad ;
Caserta, Donatella .
CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2023, 50 (10)